Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06101290 · ClinicalTrials.gov registry record · NA

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

A NA study of Prostate Cancer and Renal Cell Carcinoma, sponsored by University of California, Davis.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT06101290 is a NA study of Prostate Cancer and Renal Cell Carcinoma that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 150 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06101290, a NA study of Prostate Cancer and Renal Cell Carcinoma, is actively recruiting participants, sponsored by University of California, Davis.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

Interventions

  • DEVICE Ablative local therapy

Study Locations (1)

California

  • University of California, Davis - Sacramento

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-10-05
Est. Completion 2031-01-05
Phase NA

Sponsor

University of California, Davis

657 total trials

What the Registry Record Tells You About NCT06101290

The ClinicalTrials.gov registry entry for NCT06101290 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ablative local therapy is the first listed.

NCT06101290 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06101290 about?

NCT06101290 is a clinical study titled "Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)". This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in...

What is the current status of trial NCT06101290?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2023-10-05. Estimated completion is 2031-01-05.

What conditions does trial NCT06101290 study?

This clinical trial studies the following conditions: Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Oligoprogressive.

What interventions are being tested in trial NCT06101290?

The interventions under investigation include: Ablative local therapy (DEVICE).

Who is sponsoring clinical trial NCT06101290?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06101290 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.